Ionis Pharmaceuticals has the GF Score of 65, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Ionis Pharmaceuticals
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Ionis Pharmaceuticals GF Score Related Terms
IONS vs EXEL, BBIO, AXSM: GF Score Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's GF Score distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's GF Score falls into.
Ionis Pharmaceuticals (IONS) has a GF Score of 65 as of Jun. 26, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Ionis Pharmaceuticals and its competitors. This is near median its historical median of 67.00. Over the past decade, Ionis Pharmaceuticals' GF Score has ranged from 39.00 to 85.00.
Is Ionis Pharmaceuticals' GF Score too high?
Ionis Pharmaceuticals' current GF Score of 65 is near median its 10-year median of 67.00. Over the past 10 years, this metric has ranged from a low of 39.00 to a high of 85.00. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' GF Score compare to EXEL and BBIO?
Ionis Pharmaceuticals' GF Score of 65 can be compared against companies in the Biotechnology industry. Historically, Ionis Pharmaceuticals' own GF Score has ranged from 39.00 to 85.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current GF Score is 65, which is near median its own 10-year median of 67.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (IONS) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.12, compared to a current price of $78.34 — trading 44.8% above its estimated fair value. The current GF Score is 65, which is near median its 10-year median of 67.00. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Ionis Pharmaceuticals (IONS), the current GF Score is 65 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of $78.34 is trading 44.8% above its estimated GF Value™ of $54.12.
GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for IONS:
GF Score: 65 (near median its 10-year median of 67.00)
GF Value™: $54.12 vs. price of $78.34 (44.8% above fair value)
No single metric tells the full story. See the IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score
Get the complete analysis for IONS
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IONS has been successfully added to your 